ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2021
Kaposi Sarcoma Incidence, Burden, and Prevalence in United States People with HIV, 2000-2015.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Early antiretroviral therapy and long-term cancer risk in HIV: 9-year outcomes from the START randomized trial.BMC cancer · 2026Trial
- Cancer Risk and Mortality Following Kaposi Sarcoma Among People with HIV in the United States, 2000 to 2019.Cancer causes & control : CCC · 2026Article
- Kaposi sarcoma in solid organ transplant recipients: updates in epidemiology, diagnosis, treatment and prevention.Frontiers in immunology · 2026Review
- Prevalence and Clinical Characteristics of Visceral Involvement in HIV-Associated Kaposi Sarcoma: A Three-Year Retrospective Cohort Study at a Tertiary Care Center in Mexico.Microorganisms · 2025Article
- Demographics, Trends, and Cardiovascular Mortality in Kaposi Sarcoma Patients in the United States: An Analysis of Surveillance, Epidemiology, and End Results Database.Health science reports · 2025Article
- Genome evolution of Kaposi sarcoma-associated herpesvirus (KSHV).Journal of virology · 2025Article
- Missed Follow-Up and Kaposi Sarcoma Progression: The Consequences of Medication Non-adherence.Cureus · 2025Article
- Diffuse Kaposi sarcoma with oral involvement in a person diagnosed with human immunodeficiency virus/acquired immune deficiency syndrome: A case report.SAGE open medical case reports · 2024Article
- Transcriptional landscape of Kaposi sarcoma tumors identifies unique immunologic signatures and key determinants of angiogenesis.Journal of translational medicine · 2023Article
- Kaposi Sarcoma in the United States: Understanding Disparate Risk.JNCI cancer spectrum · 2022Article
- Incidence Trends of Kaposi Sarcoma Among Young Non-Hispanic Black Men by US Regions, 2001-2018.JNCI cancer spectrum · 2022Article
- Oncologic Treatment of HIV-Associated Kaposi Sarcoma 40 Years on.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Review
- Epidemiology of Kaposi's Sarcoma.Cancers · 2021Review
Corrections and comments
- Comment on
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe introduction of combination antiretroviral therapy (cART) has led to a significant reduction in Kaposi sarcoma (KS) incidence among people with HIV (PWH). However, it is unclear if incidence has declined similarly across key demographic and HIV transmission groups and the annual number of incident and prevalent KS cases remains unquantified.
methodsUsing population-based registry linkage data, we evaluated temporal trends in KS incidence using adjusted Poisson regression. Incidence and prevalence estimates were applied to CDC HIV surveillance data, to obtain the number of incident (2008-2015) and prevalent (2015) cases in the United States.
resultsAmong PWH, KS rates were elevated 521-fold [95% confidence intervals (CI), 498-536] compared with the general population and declined from 109 per 100,000 person-years in 2000 to 47 per 100,000 person-years in 2015, at an annual percentage change of -6%. Rates declined substantially (
conclusionsA consistent gradual decline in KS incidence has occurred among PWH in the United States during the current cART era. This decrease is uniform across key demographic and HIV transmission groups, though rates remain elevated relative to the general population. IMPACT: Continued efforts to control HIV through early cART initiation and retention in care need to be maintained and possibly expanded to sustain declines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.